AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the United States Patent Office (USPTO) has issued a patent covering ACD856, which is being developed against Alzheimer’s disease and other disorders with cognitive impairment.
USPTO has announced that they have now approved the company’s patent application in the US, which refers to ACD856, the leading drug candidate in the NeuroRestore platform, which is being developed against Alzheimer’s disease. The patent number is US 11,352,332 and the patent is valid until 2039.
ACD856 and other substances in the NeuroRestore platform stimulate several important signaling systems and signaling molecules in the brain such as BDNF (Brain Derived Neurotrophic Factor) and NGF (Nerve Growth Factor), which can lead to improved cognition. Previous preclinical studies have shown that AlzeCure’s drug candidates strengthen communication between nerve cells and improve cognitive ability, including learning and memory functions. New preclinical results also show potential neuroprotective and disease-modifying effects with these substances. The biological mechanism behind NeuroRestore enables several indications, such as Alzheimer’s and Parkinson’s disease, but also depression.
“We are continuing to build a patent portfolio for our NeuroRestore program. This is an important step for ACD856, which is in clinical development against Alzheimer’s,” said Gunnar Nordvall, Head of Chemistry and IP.
“These are very good news and constitute an important milestone for both the project and the company and further strengthens our commercial opportunities for this promising substance, which has just generated new positive clinical data,” said Martin Jönsson, CEO.